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Microvascular obstruction (MO) or no-reflow phenomenon is an established complication of coronary reperfusion
therapy for acute myocardial infarction. It is increasingly recognized as a poor prognostic indicator and marker of
subsequent adverse LV remodeling. Although MO can be assessed using various imaging modalities including
electrocardiography, myocardial contrast echocardiography, nuclear scintigraphy, and coronary angiography,
evaluation by cardiovascular magnetic resonance (CMR) is particularly useful in enhancing its detection, diagnosis,
and quantification, as well as following its subsequent effects on infarct evolution and healing. MO assessment has
become a routine component of the CMR evaluation of acute myocardial infarction and will increasingly play a role
in clinical trials of adjunctive reperfusion agents and strategies. This review will summarize the pathophysiology of
MO, current CMR approaches to diagnosis, clinical implications, and future directions needed for improving our
understanding of this common clinical problem.
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Introduction
Microvascular obstruction (MO) occurs in the setting of
reperfusion following prolonged myocardial ischemia
and provides incremental prognostic information beyond
infarct size, to which it is related. MO is characterized
by a number of ultrastructural and functional changes at
the microvascular level. Understanding these histopatho-
physiologic changes can inform the approach by cardio-
vascular magnetic resonance (CMR) to detecting MO
and our interpretation of the results and their subse-
quent clinical implications. It can also help potentially
improve how MO is assessed by CMR which has impli-
cations with regard to our understanding of infarct evo-
lution and healing as well as the evaluation of the
efficacy and mechanisms of action of adjunctive reperfu-
sion agents. This review will discuss the various
pathophysiologic derangements, both anatomic and
functional, seen at the microvascular level after myo-
cardial reperfusion; current and evolving CMR techni-
ques to assess MO and the related phenomenon of
myocardial hemorrhage; the temporal evolution ofCorrespondence: kwu@jhmi.edu
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reproduction in any medium, provided the orMO and its relationship to infarct healing, adverse LV
remodeling and clinical prognosis; clinical trial appli-
cations; and future directions.Pathophysiology of microvascular dysfunction
The contribution of microvascular injury in causing ana-
tomic myocardial “no-reflow” was first described in the
1970’s [1-3]. At that time, it had already been recognized
in other organs that despite recanalization or restoration
of arterial flow to an ischemic tissue bed, perfusion at
the tissue level may not uniformly occur. In a canine
model of ischemia-reperfusion, Kloner et al. studied the
evolution of myocardial injury using a combination of
electron microscopy and the vital dye, thioflavin-S,
which stains intact endothelium and thus causes myo-
cardial tissue receiving adequate capillary flow to fluor-
esce under UV light [1]. Epicardial coronary reperfusion
after prolonged ischemia resulted in subendocardial
regions of nonfluoresence (Figure 1) representing no-
flow or low-flow which were confirmed to have substan-
tially reduced regional blood flow measured by quantita-
tive radioactive microsphere analysis [4,5]. Because of
the wavefront of necrosis, the endocardium is the most
vulnerable area for ischemic damage.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Shown is an example of anatomic no-reflow detected by vital staining in an experimental rabbit model of coronary occlusion
and reperfusion. In Panel A, 4 short-axis slices are shown depicting the regions perfused and stained by monastral blue, which was injected
during coronary occlusion. Regions which were not perfused by the dye (i.e. do not stain blue) represent the risk area. In Panel B, the slices were
imaged under UV light to depict the fluorescent areas (greenish color) stained by thioflavin-S, which was injected following reperfusion and
stains intact endothelium. The thioflavin-S negative regions represent no-reflow,are contained within and are smaller than the risk region. Hence,
thioflavin-S negative areas depict regions of obstruction to flow despite reperfusion . Reprinted with permission from Reffelmann T, Kloner R A
Heart 2002;87:163 [2].
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cence were characterized by striking ultrastructural
changes to the microvasculature in addition to evidence
of irreversible myocardial cell injury (Figure 2). Under
normal circumstances, the capillary lumen is widely pa-
tent and lined by intact endothelial cells. In contrast,Figure 2 Schematic depicting the multiple mechanisms that contribu
Reprinted with permission from Reffelmann T, Kloner R A Heart 2002;87:164within the nonfluorescent, thioflavin-negative regions
following reperfusion, microvessel integrity was compro-
mised with intraluminal obstruction of the lumen caused
by regional swelling of the endothelial wall as well as
intraluminal protrusions and blebs of the endothelial
cytoplasm. Plugging of the microvessels by erythrocytes,te to the no-reflow phenomenon at the ultrastructural level.
[2].
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tory was external compression of the capillaries by
edematous myocytes and subsarcolemmal blebs. Based
on these experimental observations, regions of micro-
vascular injury characterized by the aforementioned
ultrastructural anatomic abnormalities and reduced re-
gional blood flow following reperfusion were termed
anatomic “no-reflow”. The quantitative extent of the
anatomic no-reflow zone is determined by how well the
vital staining dye penetrates into the ischemic tissue bed.
Although the exact mechanisms and time course of
events leading to anatomic no-reflow are unknown, it is
hypothesized that a number of interrelated factors con-
tribute [3,6]. Direct endothelial damage caused by
ischemia which leads to the observed protrusions of the
endothelial surface that encroach into and compromise
the capillary lumen likely play a direct role in the perfu-
sion deficits. Further plugging of the lumen by erythro-
cytes, fibrin, and platelet thrombi suggest that reperfusion
leads to some degree of initial flow into the microvessels
which is later compromised. Leukocyte plugging is also
observed and this may contribute not only to mechanical
obstruction but may also lead to reduced endothelial
dependent and independent vasodilation through oxida-
tive stress pathways. Neutrophils elaborate reactive oxygen
species that can impair endothelial and platelet function.
Oxygen free radicals can also promote the synthesis of tis-
sue factor which may accelerate the accumulation of
fibrin/fibrinogen.
In humans, clinical no-reflow is characterized by the
additional important contributing factors of microembo-
lization and the resultant inflammatory response [6,7].
Rupture or erosion of epicardial coronary artery plaques,
either spontaneously or induced mechanically by percu-
taneous coronary intervention, can lead to distal shower-
ing of embolic debris, consisting of atherosclerotic
plaque components and/or thrombotic material. Distal
embolization may not only contribute to mechanical ob-
struction of the microvessels but also causes an inflam-
matory response with the elaboration of vasogenic and
thrombogenic factors that further exacerbate existing
microvascular dysfunction. Hence, pathophysiologically,
no-reflow is the result of the complex interplay of a
number of related processes.
CMR techniques for microvascular obstruction
The advent of fast CMR techniques in the 1990’s facili-
tated the study of the temporal perfusion patterns within
acute reperfused infarcts following bolus administration
of gadolinium by allowing a temporal resolution of sec-
onds rather than minutes [8-10]. In seminal publications
involving an experimental animal model and a parallel
study of patients with acute reperfused infarcts [5,11],
regions of myocardial hypoenhancement within the first2 min of contrast administration were observed within
the infarct region that were characterized by signifi-
cantly reduced regional blood flow and correlated in
size with anatomic no-reflow zones measured by
thioflavin-S (Figures 3 and 4). Subsequently, these
hypoenhanced areas seen on CMR were termed micro-
vascular obstruction (MO) and since they were mea-
sured within 1–2 min of contrast administration,
represent “early” MO. The extent of early MO by
CMR was found to correlate closely with the size of
the anatomic no-reflow region by thioflavin (r = 0.91)
but was significantly smaller, measuring 61% of the
pathologic region [12]. Regions of CMR MO most
closely approximated regions within the infarct corre-
sponding to <40% of remote myocardial blood flow at
2–9 days after reperfusion, compared to thioflavin-S nega-
tive regions which corresponded to regions with <50% of
remote flow [12] . In these original studies of CMR MO, a
magnetization-driven spoiled gradient-recalled echo pulse
sequence was used that did not require adjustment of the
inversion time [13].
There have since been numerous additional approaches
to assessing CMR MO in the setting of improved pulse
sequences. First-pass perfusion sequences tracking the first
minute of gadolinium arrival and distribution within the
myocardium have been used to detect MO [15-17]
(Figure 5). However, these original sequences suffered
from relatively low spatial resolution (~2.7 × 3.4 mm)
and reduced LV coverage (maximum of 3–4 slices)
which reduce diagnostic sensitivity. Subsequently, with the
routine use of ultrafast inversion-recovery gradient echo
sequences for infarct delineation, MO is increasingly
assessed on late gadolinium enhanced (LGE)(Figure 5) as
well as early gadolinium enhanced (EGE) images [18-20]
with the advantage of improved spatial resolution as well as
complete LV coverage. Assessing MO on EGE requires a
fixed, high inversion-time (TI) and is generally performed
at ~2-4 min following contrast administration (Figure 6).
With the recent advent of accelerated high-resolution per-
fusion sequences (1.5 mm × 1.5 mm spatial resolution, 8
slices acquired over 2 R-R intervals) [21], it is now possible
to detect true first pass MO and quantify it for the entire
LV (Figure 6).
Because gadolinium is not a pure intravascular agent
and extravasates into the interstitium within minutes fol-
lowing administration, it gradually diffuses into the ini-
tially hypoenhanced zone. Hence, the size of MO
decreases over time from contrast administration, the
largest being during first pass and the smallest during
LGE (the latter also termed “persistent” MO in the lit-
erature). Although there is a high concordance and cor-
relation amongst the 3 measures of MO (r = 0.91
between FP and EGE; r = 0.55-0.78 between EGE and
LGE MO) [16,21], MO will be detected more frequently
Figure 3 A shows the signal intensity curves following gadolinium bolus administration in infarct regions which become hyperenhanced
compared to the persistent hypoenhancement within the infarct core. Historically, hypoenhancement was measured at ~1 min (black arrow)
following contrast administration. Reprinted from Judd, RM et al. Circulation 1995;92:1902–10 [5]. B shows the correlation between MO detected
by thioflavin-S (left panel) compared to CMR (right panel). Reprinted from Rochitte C E et al. Circulation 1998;98:1006–1014 [14].
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14% by LGE in one study [21]). Amongst the 3 mea-
sures, there was the least variability in MO quantification
using the LGE method [21]. First-pass MO may be overes-
timated by the concomitant presence of significant epicar-
dial coronary stenoses which impede contrast delivery.
Late or persistent MO presence and extent will depend
upon the timing of image acquisition following gadolinium
administration, particularly in the presence of less severe
microvascular dysfunction.
Time course of MO post-infarction
MO extent varies as a function of time from the acute
ischemic event. Experimentally, it has been demon-
strated that there is an expansion of the anatomic no-
reflow area by thioflavin-S in the hours following reper-
fusion, with a tripling in size between 2 min and 2–4 hand a further smaller increase up to 8 h following reper-
fusion [4,22,23]. Following an initial hyperemic phase
within the first 2 min of reperfusion, there is a marked,
progressive decline in myocardial blood flow which plat-
eaus at around 50% of normal flow, which supports these
findings. Experimental studies using CMR, in addition to
thioflavin staining and radioactive microspheres to meas-
ure blood flow, have also suggested that MO extent
increases from 1–2 h to 24 h post-reperfusion and may
further increase up to 48 h post-reperfusion [14,24,25].
However, there have not been any confirmatory studies in
humans to demonstrate expansion of MO at any time-
point post-reperfusion.
It is increasingly apparent that the temporal course of
MO may vary in the subsequent days to weeks as infarct
healing ensues and may in fact influence LV remodeling.
Both animal models and humans studies, using both CMR
Figure 4 MO regions depicted on first pass imaging CMR (top panel) which though smaller, persist on LGE images (bottom panel).
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demonstrate that microvascular dysfunction may persist up
to 1 month post-reperfusion [26-28]. Persistence of MO at
1 month was associated with worse regional wall motion,
scar thinning, and infarct expansion [26,27]. In a rat model,
at 4 weeks post-reperfusion, regions of anatomic no-reflow
remain visible and are associated with a markedly reduced
capillary density and decreased myocardial blood flow [27].
A recent study using a porcine infarct model lends further
insight by showing that histopathologic evidence of
obstructed capillaries filled with necrotic debris can be seen
at 2 weeks but the infarct is replaced by extensive collagen
deposition and fibrosis at 6 weeks [29]. However, particu-
larly in patients, microvascular dysfunction may in fact re-
solve much earlier than 1 month (Figure 7), as several
CMR and myocardial contrast echocardiography studies
have shown, and earlier resolution appears to correlate withFigure 5 MO (arrow) within a lateral infarct shown using high-resolut
fixed TI of 440 msec (middle panel), and LGE (right panel). Reprinted w
(1):11–33 [21].improved functional recovery post-MI and outcome
[28,30-32]. The severity of MO likely affects its degree of
persistence and may account for conflicting data regarding
temporal changes in the size of MO in experimental studies
with some studies showing no significant change in MO
extent between 2 and 9–10 days [12,25] and others in
which MO appeared smaller at 1 week [29,33]. Also con-
tributory may be the complex pathophysiologic
mechanisms of MO that can be differentiated as
“structural” versus “functional” [34]. “Structural” or ir-
reversible alterations to the microvascular bed can be
characterized by the luminal obstruction by cellular
debris and endothelial wall damage. In humans in
particular, there may be a larger contribution of
“functional” or potentially reversible changes such as
microvascular spasm and microembolization which
promotes vasoconstriction via the elaboration of vasoactiveion k-t SENSE accelerated first pass imaging (left panel), EGE with
ith permission from Mather et al. J Cardiovasc Magn Reson 2009;11
Figure 6 Shown are corresponding short-axis slices from a 62-year-old gentleman with anterior ST elevation MI who was treated with
primary PCI. Using the kt-SENSE first-pass perfusion imaging technique on day 2 post MI with 0.1 mmol/kg intravenous gadolinium contrast,
there is an area of persistent hypoperfusion corresponding to MO. There is substantial improvement at re-imaging on day 7 (Panel b). (Image
provided courtesy of Ananth Kidambi, BMBCh; Adam N. Mather, MBBS; and Sven Plein, MD, PhD; Multidisciplinary Cardiovascular Research Centre
& Leeds Institute of Genetics, Health, and Therapeutics, University of Leeds, Leeds, United Kingdom.).
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reduced myocardial perfusion reserve which can be poten-
tially assessed by adenosine myocardial perfusion [36,37].
The time courses of structural and functional no-
reflow may thus differ and explain in part, variabilityFigure 7 The effect of MO on adverse LV remodeling is shown in a pa
infarction (Panels A & B) and at 9 month follow-up post-infarction (Pa
anterior descending coronary artery, there was a large region of persistent
LV (Panel A). Acutely (Panel B), LVEF measured 27% and LV volumes were
systolic (LVESV) of 141 ml. At 9 month follow-up, there was LV apical aneur
reduced LVEF of 25% and further enlargement of the LV with LVEDV of 291in the time course data. Functional no-reflow may
perhaps resolve more quickly as vasoactive/proin-
flammatory mediator levels return to normal post-
infarction compared to structural no-reflow that
requires prolonged infarct tissue healing.tient. CMR-LGE and cine images are shown acutely post-
nels C & D). Despite successful epicardial reperfusion of the left
MO associated with a large anteroapical infarct measuring 49% of the
enlarged with LV end-diastolic volume (LVEDV) of 192 ml and end-
ysm formation with infarct wall thinning (Panel C) with a persistently
ml and LVESV of 218 ml (Panel D).
Table 1 Clinical studies of CMR MO








Wu et al. [43]
N = 44
• Early (yes/no) 10 days 25% MO predicted MACE at 16 mos. independently of infarct size
Hombach et al.
[20] N = 110
• LGE (yes/no) 6 days 46% Late MO predicted MACE at 7.5 mos., independently of LVEF, LVEDV,
infarct size
Bruder et al. [44]
N = 67
• EGE 5 days 61% EGE MO>0.5% predicted 1-yr MACE independently of LVEF & infarct size
Cochet et al. [45]
N = 184
• First-pass LGE 3-7 days 69% (FP) Late MO predicted 1-yr MACE independently of LVEF & infarct size
47% (LGE)
De Waha et al. [46]
N = 408
• EGE LGE 3 days 81% (FP) Late MO (presence/amount) better predicted MACE at 19 mos. with
incremental value over LVEF & infarct size
73% (LGE)
Negative studies
Bodi et al. [47]
N = 214
• LGE (yes/no) 7 days 31% Infarct transmural extent & wall motion score independently predicted
MACE at 1.5 years.
Larose et al. [48]
N = 103
• First-pass <12 h Not reported Infarct size was the strongest predictor of 6 mo. LVEF & 2-yr MACE
6 months
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remodeling
With the caveat that many of the studies were rela-
tively small, which limits the robustness of multivari-
ate modeling, CMR MO has been found to be
predictive of clinical outcome (Table 1), independently
of or when adjusted for other indices such as infarct
size and LVEF. This is consistent with the results of
studies using other imaging technique such as myocardial
contrast echocardiography and coronary angiography to
assess no-reflow [23,38-42]. Many of these patient out-
come studies also showed a relationship between presence
of MO and adverse LV remodeling (Table 2) with reduced
global systolic function and larger LV volumes at follow-
up (Figures 8 and 9), suggesting a possible mechanism for
the poor prognosis. Experimental studies have supported
these observations. In an animal model, a larger region of
anatomic no-reflow was associated with thinner infarct
walls and worse infarct expansion [27]. Theoretically, ob-
struction of blood flow to the infarct core could limit the
delivery and transit of cellular components such as macro-
phages required for phagocytosis of cellular debris and
nutrients needed for optimal infarct healing [23]. Add-
itionally, obstructed microvessels may limit the future po-
tential for collateral blood flow development [23].
An experimental model using myocardial tissue tag-
ging suggests a possible mechanism linking MO to poor
infarct remodeling: MO may cause heterogeneity in local
myocardial tissue properties across the infarct wall that
could adversely affect wall stress and subsequent infarct
healing [25]. In a canine model of acute reperfused MI,
myocardial deformation was measured at 4–6 h, 48 h,and 10 days post-reperfusion. MO extent, measured
both early (4–6 h post-reperfusion) and at 48 h, was a
stronger predictor of increases in LV volumes than in-
farct size. There were demonstrable changes in myocar-
dial deformation up to 48 h post-reperfusion in the
infarcted and adjacent myocardium based upon the
amount of MO, expressed as a percent of infarct size.
Compared to animals with MO comprising <35% of the
infarct volume, in those with MO comprising >35% of
the infarct volume, infarcted myocardial segments exhib-
ited significantly less stretching in the longitudinal direc-
tion; noninfarcted, adjacent regions exhibited reduced
radial thickening; and there was a reduction in the first
principal strain. This suggests that infarcts with greater
amounts of MO are characterized by increased stiffness
and reduced myocardial deformation in both the nec-
rotic region and also the adjacent, noninfarcted region.
Changes within the infarct region were seen at 4–6 h
and preceded the alterations in the adjacent segments,
which were not observed until 48 h post-reperfusion.
Thus, increased myocardial stiffness and reduced elasti-
city in the infarcted regions with large amounts of MO
could result in increased local wall stress that subse-
quently limits systolic shortening in adjacent segments,
all of which may lead to adverse LV remodeling.
Most of the human studies showing a positive independ-
ent association between MO and clinical outcome tended
to measure MO within 3–7 days post-reperfusion and uti-
lized the LGE technique for assessment of MO. There have
been a few studies that have suggested that MO is not inde-
pendently predictive of outcome, after controlling for in-
farct size [47,48] (Table 1). In one of the studies, MO was
Table 2 CMR MO and LV remodeling in patients








Wu et al. [43] N= 44 • Early • 10 days 25% Early MO predicted LV remodeling
• 16 months
Hombach et al. [20]
N = 110
• LGE • 6 days 46% Late MO, infarct size predicted LV remodeling
• 7.5 months
Nijveldt et al. [49] N = 60 • First-pass • 2-9 days • 68% (FP Late MO was the strongest predictor of LV remodeling
• LGE • 4 months • 57% (LGE)
Orn et al. [30] N= 42 • First-pass • 2 days Day 2: Late MO was associated with the worst LV remodeling
indices at all timepoints
• LGE • 1 week • 38% (FP)
• 2 months • 33% (LGE)
• 1 year • 1 week:
• 34% (FP)
• 21% (LGE)
Weir et al. [50] N = 100
(LVEF < 40%)
• Early • 4 days • 69% (Early) Late MO was associated with the greatest change in
LV remodeling indices
• LGE • 24 weeks • 56% (LGE)
Negative studies
Mather et al. [33] N = 48 • LGE • 2 days Day 2 &
1 week
1 week infarct size & LVEF best predicted 3 month
infarct size & LVEF
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which may have underestimated the true incidence of MO
since MO likely increases in size over the first 24–48 h
post-reperfusion. In the other study, the study results may
have been influenced by heterogeneity in the times to actual
epicardial revascularization which will affect the evolution
of MO [51].
MO and infarct hemorrhage
As part of the disruption to the microvasculature
observed upon reperfusion, large gaps can be seen in
the endothelial wall that cause extravasation of red
blood cells, i.e. hemorrhage. In experimental models
performed as early as the 1980’s, it was observed that
any hemorrhage was limited to the region of severe
microvascular injury,. lagged behind the no-reflow
process and its extent was directly proportional to
the duration and severity of the preceding ischemia
(with the severity of ischemia determined predomin-
antly by collateral flow) [22,52-58]. Specifically, myo-
cardial hemorrhages occurred when myocardial blood
flow during the time of coronary occlusion prior to
reperfusion was <21% of control [54]. Macroscopic
hemorrhage does not occur in the absence of reperfu-
sion, i.e. in the presence of a persistent coronaryocclusion [55] (Figure 10). The extent of hemorrhage
has been found to be highly correlated with patho-
logic infarct size (r = 0.90) and increases in proportion
to the occlusion time prior to reperfusion but is inde-
pendent of thrombolytic therapy (i.e. a lytic state does
not increase the amount of hemorrhage seen) [59-61].
Hemorrhage can be assessed using T2-weighted and
T2* imaging. The appearance of hemorrhage on MRI is
based upon the paramagnetic effects of hemoglobin deg-
radation products [63,64]. Initially, hemorrhage may
consist of oxyhemoglobin which lacks paramagnetic
effects. Subsequently, probably within the first few days
after acute MI, oxyhemoglobin denatures into deoxyhe-
moglobin which does exert paramagnetic effects and will
significantly reduce the T2 time. Deoxyhemoglobin is
then gradually converted over the following few days
into methemoglobin, which is strongly paramagnetic
with respect to both T1- and T2-weighted sequences.
After ~2 weeks, methemoglobin is converted into hemo-
siderin which is contained within macrophages and
also results in low T2 values. Hence, acutely post-MI,
hemorrhage can be visualized on CMR as hypoen-
hanced regions surrounded by elevated signal intensity
representing myocardial edema on T2-weighted im-
aging and most studies show that hemorrhage is limited
Figure 8 The presence and persistence of MO can predict how well the LV remodels in the subsequent year. Reprinted with permission
from: rn S et al. Eur Heart J 2009;30:1978–1985 [30].
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ation of human autopsy specimens in 2 cases showed a
close correlation between pathologic hemorrhage and
hypoenhanced signal intensity on T2 sequences [68].
However, MVO without hemorrhage can also result in
hypoenhanced regions seen on T2-weighted sequencesFigure 9 Gross anatomic features (Panels A & C) of a bland, white no
reperfused (Panel C, arrows) acute MI. Coronary cross sections (Panels B
anterior descending artery (LAD) of the bland infarct while the hemorrhage
arrow) with residual mural thrombus (Panel D, orange arrowheads). Reprint
[62] (Original image provided courtesy of Professor Cristina Basso, Departm
Padua Medical School, Padova, Italy.).[69] and both can appear as rims of persistent hypoen-
hancement on LGE [70,71] (Figure 11). A potentially
promising approach in differentiating MVO with and
without hemorrhage could be the method of direct
T2 quantification, which has yielded more robust
findings for the detection of myocardial edeman-reperfused (Panel A, white arrows) and a hemorrhagic, red
& D) revealed an occlusive thrombus (Panel B, black arrow) in the left
infarct was associated with recanalization of the LAD (Panel D, black
ed with permission from Basso C, Thiene G. Heart 2006;92:1559–1562
ent of Medical Diagnostic Sciences and Special Therapies, University of
Figure 10 Shown are short axis images from a 48-year-old gentleman who presented with inferior ST-elevation and received primary
percutaneous intervention to the RCA. CMR on day 2 post MI demonstrated an area of hypointense signal on T2-weighted imaging (Panel a),
but no signal hypointensity on T2* imaging (Panel b). This area was confirmed to represent MO on early gadolinium imaging (Panel c).
Intramyocardial hemorrhage results in decreased signal intensity on T2* imaging, and the absence of this feature reflects a lack of visible
hemorrhage within the area of MO. (Image provided courtesy of Ananth Kidambi, BMBCh; Adam N. Mather, MBBS; and Sven Plein, MD, PhD;
Multidisciplinary Cardiovascular Research Centre & Leeds Institute of Genetics, Health, and Therapeutics, University of Leeds, Leeds, United
Kingdom.).
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version recovery [72,73]. Within the infarct core, T2
mapping demonstrates significant reductions in T2
values corresponding to LGE MO (Figure 11).
Whether or not such a technique can also differenti-
ate between MO with and without hemorrhage by
detecting gradations in reduced T2 values requires
further investigation.
As opposed to T2 relaxation which depends primarily
on spin-spin interactions, T2* decay is caused by a com-
bination of spin-spin relaxation and magnetic field in-
homogeneity [74]. Because iron deposits and blood
products cause magnetic field inhomogeneities, T2* im-
aging has been used to measure myocardial iron depos-
ition in the setting of iron overload cardiomyopathies
and recently applied to detecting hemorrhage in the set-
ting of acute reperfused MI [75-78]. Since the paramag-
netic effects of hemoglobin byproducts on T2* is even
stronger than on T2, T2*-weighted sequences should gen-
erally exhibit higher sensitivity for hemorrhage [78-80]. InFigure 11 T2-weighted short tau inversion recovery (STIR), T2 map an
similar mid-short axis plane – are shown from CMR examination perf
myocardial infarction. CMR performed 1 day following percutaneous coro
yielded a calculated LVEF of 55%. STIR imaging suggested increased signal
abnormality within this region. Quantitative T2 mapping shows a region of
obstruction (MO). Mean T2 values in the edematous region (dotted line), M
48 msecs. 10 min after intravenous gadolinium-based contrast administrati
provided courtesy of Subha V. Raman, MD, MSEE; Davis Heart and Lung Rea recent experimental canine model, T2* imaging was
compared to pathologic analysis of the infarct region at
day 3 post-reperfusion [76]. Gross hemorrhage was limited
to those animals with the largest infarct sizes and extents of
MVO. Pathologically, all animals with hemorrhage had evi-
dence of MVO. There was high concordance between
hemorrhage detected pathologically and that detected by
T2* imaging (kappa=0.96, P <0.01). The size of the
hemorrhagic area was highly correlated with that measured
pathologically (r = 0.91, p<0.01), though CMR overesti-
mated the extent (mean difference of 2.4±1.4%). The
amount of hemorrhage was always smaller than the
amount of MVO and was contained within it. Use of T2*
sequences has the potential to improve the differentiation
of MVO alone from MVO with hemorrhage: hemorrhage
will be accompanied by reduced, below normal T2* levels
whereas MVO alone will not [71] (Figure 12).
The time course over 6 weeks of MO and hemorrhage
was further examined recently in a porcine model of acute
reperfused myocardial infarction [29]. MO was assessedd late gadolinium enhancement (LGE) images – all obtained in a
ormed in a 53 year-old male who suffered ST-elevation
nary revascularization of a large obtuse marginal coronary artery
intensity in the inferolateral wall (arc), but does not demonstrate an
increased T2 with a hypointense core indicating microvascular
O (black arrow) and remote myocardium (solid circle) were 71, 59 and
on, LGE confirms a region of MO in this post-STEMI patient. (Image
search Institute, The Ohio State University, Columbus, Ohio.).
Figure 12 The potential for T2* imaging to improve the differentiation between MO with and without hemorrhage is shown. Panel A
shows uniform hyperintensity on T2-SPIR (spectrally selective inversion recovery) imaging despite a region of persistent MO on LGE (Panel C). In
Panel B, a small region of decreased T2* is shown, which is much smaller than the MO region, suggesting that much of MO region is in fact non-
hemorrhagic and shows normal T2* values. (Reprinted with permission from: O’Regan DP et al. Heart 2010; 96:1885-1891[78]). See also the
imaging vignette from Cannan C et al. JACC: Cardiovascular Imaging 2010; 3(6):665–668 [71].
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1, 2, 4, and 6 weeks post-reperfusion. MO extent was the
largest at 2 days with gradual reduction over the ensuing
2 weeks and complete resolution by week 4. T2* values
reflecting hemorrhage followed the same temporal course
with the lowest T2* levels seen acutely in the hemorrhagic
core which gradually normalized to control levels at
4 weeks. Detailed histopathologic analysis was also per-
formed and compared to the CMR findings. At day 2
post-infarct, T2* signal voids corresponded to histopatho-
logic areas of extensive hemorrhage within the infarct. At
week 2, histologic sections within the MVO region contin-
ued to show obstructed microvessels with necrotic debris
and macrophage infiltration. Iron deposition within the
MVO region corresponded to T2* signal voids at this time
point. By 6 weeks post-MI, the infarct region was charac-
terized by extensive collagen deposition and myocardial fi-
brosis with no evidence of iron deposition consistent with
resolution of the hemorrhage and MVO process. In this
study, only infarcts with hemorrhage were studied.
Subsequent clinical studies have supported these experi-
mental findings. In patients, the extent of late MO has
been found to be highly correlated with the size of the
hemorrhage area (r2 = 0.87, p < 0.001) and interestingly,
the correlation with early MO was less robust (r2 = 0.30,
p < 0.003) [78]. Several other studies have shown that the
presence of hemorrhage is a strong predictor of adverse





Prevalence of MO &
hemorrhage (H)
Ganame et al. [66]
N = 98
• EGE (MO) • 1 week 64% (MO)
• T2W (H) • 4 months 24% (H)
Mather et al.
[33,81] N= 48
• EGE (MO) • Day 2 63% (MO)
• T2W &
T2* (H)
• 3 months 25% (H)
Eitel et al. [67]
N = 346
• LGE (MO) • Day 3 70% (MO)
• T2W (H) 35% (H)suggest that hemorrhage reflects more severe, and possibly
irreversible, persistent, “structural” rather than potentially
reversible, “functional” microvascular injury and its reso-
lution parallels that of anatomic MVO as infarct healing
ensues. It may thus be a more specific marker of adverse
events because it reflects irreversible, structural injury to
the microvasculature, but this requires further investiga-
tion and confirmation.
Clinical trial applications
MO is increasingly incorporated into clinical trial meth-
odology as a surrogate clinical outcome in studies inves-
tigating adjunctive reperfusion agents and strategies,
particularly when the treatment has the potential to dir-
ectly impact microvascular function [82-92]. On the
web-based clinical trial registry, www.clinicaltrials.gov,
there are currently 25 open studies in which micro-
vascular obstruction is an endpoint and there are an
additional 22 closed studies (http://clinicaltrials.gov/ct2/
results?term=microvascular+obstruction). In doing so,
early signals of detrimental effects may be detected be-
fore larger scale trials are embarked upon. An example
of this was observed in a 51 patient randomized study of
erythropoietin (EPO), in which there was a doubling of
MO incidence in the treated group, associated with
increased LV volumes acutely post-MI [83]. Although
the mechanisms for this are not definitively known, the
contribution of increased platelet reactivity and theFindings
Presence of hemorrhage & infarct size were the strongest
predictors of LV remodeling
Presence of hemorrhage, LVEF & infarct size were the best
predictors of adverse remodeling
Presence of hemorrhage & LVEF were the best predictors of
6 month MACE
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ation for the observed increase in MO. Notably, there
was a nonsignificant trend toward an increased infarct
size in the treated group in this study. In a subse-
quent trial in which a single high dose of EPO was
administered to 110 patients, there was no change in
infarct size at 3 months but MO incidence was sig-
nificantly decreased acutely [93]. The authors postu-
lated that the higher dose and earlier delivery of EPO
may have accounted for the differences in MO rates.
Nonetheless, both of these studies highlight the po-
tential for MO evaluation to provide better study
power as an endpoint compared to infarct size.
A potentially valuable application is in the evaluation
of stem cell therapy for acute MI, particularly when such
cells are delivered via the intracoronary route. Many of
such published human studies have used CMR to pre-
dominantly assess LVEF and LV volumes with an in-
creasing number also assessing infarct size [94-99] and
MO [96,100-103]. As larger efficacy trials are being con-
ducted and planned, incorporating systematic MO as-
sessment may help in identifying which patients may
derive the most benefit (i.e. larger amounts of MO could
theoretically impair stem cell engraftment); optimizing
the timing of cell delivery in relation to MO temporal
evolution; and understanding possible pathophysiologic
benefits of stem cells (i.e. is there neovascularization or
restoration of microvascular function or are there detri-
mental effects on microvascular perfusion due to cellular
plugging of microvessels [104]).
Ongoing controversies and future directions
Currently, the CMR assessment of MO is limited by the
lack of standardization with regard to when temporally
MO is measured, both with respect to the time following
contrast administration and the time post-reperfusion.
There is likely to be marked fluidity of MO presence
and extent as infarct healing ensues and as a function of
inter-patient variability in the degree/reversibility of
microvascular dysfunction. FP perfusion and EGE/LGE
techniques, particularly when measured at only one
timepoint post-reperfusion, may overestimate the extent
of structural, anatomic MO since other reversible factors
may affect gadolinium contrast kinetics, such as extrinsic
compression of the microvessels or vasoconstriction,
which may resolve much more quickly than anatomic MO.
Whether or not the assessment of myocardial hemorrhage
improves the diagnostic utility of MO remains undeter-
mined, as does the optimal method to detect hemorrhage.
A certain amount of hemorrhage is seen in all reperfused
infarcts and likely reflects the severity of the ischemic
microvascular injury. MO by itself, without hemorrhage,
may limit the effective amount of tissue water because of
the associated cellular debris and obstructed capillary flowthereby reducing the supply of protons within the infarct
volume and thus lead to areas of low T2. Newer techniques
such as T2* sequences could theoretically be more sensitive
and specific for detecting severe anatomic microvascular in-
jury, specifically, the consequences of endothelial injury and
subsequent extravasation of blood, by specifically measur-
ing hemoglobin byproducts. However, larger studies are
needed to examine the comparative diagnostic performance
of various measures of CMR microvascular dysfunction in
predicting adverse LV remodeling and clinical outcome.
Consideration should be given to examining MO and
infarct hemorrhage at various time points within the
first 7–10 days post-MI to perhaps distinguish be-
tween functional from anatomic MO,, particularly in
clinical treatment trials of adjunctive reperfusion
agents or strategies.
Our knowledge regarding how CMR measures of MO
directly compare with indices of microvascular dysfunc-
tion assessed by other imaging modalities remains incom-
plete but an increasingly number of studies are addressing
this question. CMR has been compared with acute electro-
cardiographic ST segment resolution [49,105-108], angio-
graphic measures [49,107,109-111], myocardial contrast
echo [12,38] and recently, multidetector cardiac CT
[112-114]. The methods generally correlate fairly well
with one another in terms of diagnostic utility for
MO. However, there is no consensus regarding the “best”
method to assess MO in terms of pathophysiology, diag-
nostic performance, and prognostic implications. Given
that angiographic indices and electrocardiographic ST seg-
ment assessment can be performed acutely during occlu-
sion/reperfusion, they may in fact be complementary to
the CMR indices, which are generally assessed later in the
post-MI period. Further investigation is warranted as to
the comparative roles and diagnostic and prognostic value
of the different imaging methods to assess MO, particu-
larly since many are increasingly being used as surrogate
clinical trial endpoints.
Conclusions
In summary, microvascular obstruction and the related
phenomenon of myocardial hemorrhage, occur com-
monly following reperfusion for acute MI and can be
assessed using various CMR techniques, including first
pass perfusion, early and late gadolinium enhancement,
and recently, T2 and T2* techniques. Both experimental
and human studies support the association between the
increasing incidence and extent of MO and worse LV re-
modeling, likely as a result of the adverse consequences
of increased myocardial stiffness and reduced deform-
ation in both the infarct and adjacent regions. The ad-
verse effect on the infarct healing process in turn may
explain the worse prognosis observed with MO. How-
ever, there has not yet been definitive proof that MO
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http://www.jcmr-online.com/content/14/1/68can be modified by any intervention and in so doing,
results in improved outcome. This is in part due to the
lack of a standardized approach to assessing MO, which
will need to be established, both with respect to the
optimal CMR protocol as well as the timing of evalu-
ation post-MI. Thus, while further validation and prog-
nostic studies with larger sample sizes are needed to
define its role both in clinical risk stratification and as a
research tool, CMR MO assessment will be critical to
advancing the treatment of patients with acute MI.
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